Wilson Daniel J, Schutte Scott M, Abel Steven R
JFK Medical Center, Atlantis, FL, USA
St Mary's Medical Center, Evansville, IN, USA.
Ann Pharmacother. 2015 Jun;49(6):727-34. doi: 10.1177/1060028015574593. Epub 2015 Feb 27.
To review the commercially available ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs), identify opportunities for therapeutic substitutions within and outside of their Food and Drug Administration (FDA)-approved indications, and identify clinically superior drugs within the class for specific indications.
A PubMed search (1992 through January 2014) was performed on the terms diclofenac, ketorolac, flurbiprofen, bromfenac, and nepafenac.
Clinical trials, meta-analyses, and review articles were evaluated if they were written in English and pertained to human subjects. Studies were excluded if they were in vitro studies, solely evaluated pharmacokinetic or pharmacodynamic properties, did not relate to the topical ophthalmic route, did not evaluate the FDA-approved indications of any available ophthalmic NSAID, or compared a reviewed drug with a nonreviewed drug (without placebo comparison).
A total of 67 articles met the criteria for evaluation. Article quality, study design, and dosing of the medications were assessed to determine the clinical applicability of the results. The quality of the article was determined using the Oxford Centre for Evidence-based Medicine Levels of Evidence 1.
Many formulations of the 5 reviewed NSAIDs have been studied across the 4 primary indications. These indications are (1) pain and inflammation associated with cataract surgery, (2) pain associated with corneal refractive surgery, (3) inhibition of intraoperative miosis, and (4) seasonal allergic conjunctivitis. Several studies have directly compared drugs within this class and have identified instances in which certain selections are therapeutically superior or equivalent to another. This information provides practitioners with guidance in selecting an optimal medication.
回顾市售眼科非甾体抗炎药(NSAIDs),确定在其美国食品药品监督管理局(FDA)批准的适应症范围内外进行治疗替代的机会,并确定该类别中针对特定适应症临床上更优的药物。
对双氯芬酸、酮咯酸、氟比洛芬、溴芬酸和奈帕芬酸等术语进行了PubMed检索(1992年至2014年1月)。
如果临床试验、荟萃分析和综述文章用英文撰写且涉及人类受试者,则对其进行评估。如果研究是体外研究、仅评估药代动力学或药效学特性、与局部眼科给药途径无关、未评估任何可用眼科NSAID的FDA批准适应症,或比较一种被审查药物与未被审查药物(无安慰剂对照),则将其排除。
共有67篇文章符合评估标准。评估文章质量、研究设计和药物剂量以确定结果的临床适用性。文章质量使用牛津循证医学中心证据水平1来确定。
已针对4个主要适应症对5种被审查的NSAIDs的多种制剂进行了研究。这些适应症为:(1)与白内障手术相关的疼痛和炎症,(2)与角膜屈光手术相关的疼痛,(3)抑制术中瞳孔缩小,以及(4)季节性过敏性结膜炎。多项研究直接比较了该类别中的药物,并确定了某些选择在治疗上优于或等同于另一种选择的情况。这些信息为从业者选择最佳药物提供了指导。